How Vilon Lowers Prolactin to Restore Male Sexual Function
I took a grey-market immune peptide to rejuvenate my aging thymus—and accidentally discovered a central switch for central libido.
Here at Conquer Mortality, I’ve been tracking, stacking, and tinkering with my own biology since the early 2000s, long before GLP-1s made peptides mainstream. So a while back, when I kept seeing chatter on X about the dipeptide Vilon, I did what any sane person would do: I tracked down a sketchy grey market vendor and bought some. Vilon is primarily known as a thymic bioregulator—an immune-modulating peptide designed to rejuvenate the thymus. Fast forward a few weeks.
The vial arrived, and I took a 2mg dose intranasally before bed, expecting a shift in my immune markers over the coming months. About an hour later, I noticed something immediately verifiable: I was rock hard.
Releasing the Prolactin Brake
Vilon lowers blood prolactin, removing the primary chemical brake that aging puts on male sexual function. When I went digging through the literature to explain my highly localized reaction to an immune peptide, I found a 2006 Russian study detailing exactly how this works. Researchers wanted to model sexual function loss, so they used hemigonadectomised male rats—removing one testicle from older animals. This induced a hypogonadal status that mirrored advanced aging. When they gave these damaged models Vilon, their sexual function reactivated.
The mechanism isn’t what most doctors prescribe for a fading sex drive. Most mainstream erectile dysfunction treatments rely on localized vascular dilation—forcing blood vessels open to treat a peripheral symptom. Vilon does the opposite by operating centrally, removing the hormonal brakes that stop the specific process of arousal before it even starts. The researchers noted that as we age, we produce too much prolactin.
This prolactin hypersecretion is one of the main factors leading to age-related decline in sexual function. Vilon lowers that prolactin content in the blood.
But it doesn’t stop with prolactin. The arousal is a top-down nervous system event. The 2006 Russian study confirms that Vilon reaches the hypothalamus and changes the content of hypothalamic neurotransmitters, which revamps the animal’s neuroendocrine status. By rewiring this central network, the peptide modulates other major pituitary outputs, specifically altering the levels of Luteinizing Hormone (LH) and Adrenocorticotropic Hormone (ACTH). You aren’t just artificially pumping blood; you are remodeling the central hormonal cascade.
There is a gap between controlled clinical trials and what I did in my bathroom. The research team used a 50 microg dose per rat, delivered via systemic injection. My self-experiment was a 2mg dose given via intranasal administration, aiming for mucosal absorption directly to the brain.
Because Vilon is constrained to the grey market and foreign clinical data, we have zero safety data on how a 2mg dose translates to human biology over time. There is a disparity between the 50 microg dose used in the aging models and the undocumented pharmacokinetics of a 2mg intranasal protocol. We do not know the half-life or the systemic saturation limits when you sniff fifty times the clinical baseline dose directly into your nasal cavity.
Peptides are routinely marketed as targeted tools, but if you remove the central, chemical brakes on a core neurobiological pathway, your body will let you know. If you are experimenting with an aging immune system and suddenly find yourself pitching a tent at 11 PM, the peptide is probably legitimate.